NCT00627003 - A Study to Evaluate the Efficacy and Safety of Cabergoline Compared With Placebo for the Treatment of RLS | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

November 30, 2002

Study Completion Date

May 31, 2003

Conditions

Restless Legs Syndrome

Interventions

DRUG

Cabergoline

Cabergoline oral tablets administered once daily in the evening: 0.5 mg daily on Days 1 to 3, 1.0 mg daily on Days 4 to 7, 1.5 mg daily on Days 8 to 10, and 2.0 mg daily on Days 11 to 14, followed by a stable dose for an additional 3 weeks

OTHER

Placebo

Placebo oral tablets administered daily for 5 weeks